Sara Croce

Dr. Sara Croce


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Miriana D'AlessandroMiriana D'Alessandro
Miriana D'Alessandro
SGSara Gangi
Sara Gangi
PSPiera Soccio
Piera Soccio
ECElisabet Canto
Elisabet Canto
RORubén Osuna-Gómez
Rubén Osuna-Gómez
Elena BargagliElena Bargagli
Elena Bargagli
Diagnosis of interstitial lung diseases (ILD) is difficult to perform. Extracellular vesicles (EVs) facilitate cell-to-cell communication, and they are released by a variety of cells. Our goal aimed to investigate EV markers in bronchoalveolar lavage (BAL) from idiopathic pulmonary fibrosis (IPF), sarcoidosis and hypersensitivity pneumonitis (HP) cohorts. ILD patients followed at Siena, Barcelona and Foggia University Hospitals were enrolled. BAL supernatants were used to isolate the EVs. They were characterized by flow cytometry assay through MACSPlex Exsome KIT. The majority of alveolar EV markers were related to the fibrotic damage. CD56, CD105, CD142, CD31 and CD49e were exclusively expressed by alveolar samples from IPF patients, while HP showed only CD86 and CD24. Some EV markers were common between HP and sarcoidosis (CD11c, CD1c, CD209, CD4, CD40, CD44, CD8). Principal component analysis distinguished the three groups based on EV markers with total variance of 60.08%. This study has demonstrated the validity of the flow cytometric method to phenotype and characterize EV surface markers in BAL samples. The two granulomatous diseases, sarcoidosis and HP, cohorts shared alveolar EV markers not revealed in IPF patients. Our findings demonstrated the viability of the alveolar compartment allowing identification of lung-specific markers for IPF and HP.

31 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
BSBruno Sposato
Bruno Sposato
LLLeonardo Gianluca Lacerenza
Leonardo Gianluca Lacerenza
SCSara Croce
Sara Croce
EPElisa Petrucci
Elisa Petrucci
VFValentina Fabbrini
Valentina Fabbrini
Marco Scalese UrciuoliMarco Scalese Urciuoli
Marco Scalese Urciuoli
Background/Objective: Single-inhaler triple therapy (SITT) with budesonide/formoterol/glycopyrronium (B/F/G) is an option for COPD patients with frequent exacerbations. We evaluated its long-term efficacy in real life on emergency room visits/hospitalizations (primary endpoints), lung function, oral corticosteroid (OC), antibiotics and salbutamol (SABA) prescriptions (secondary endpoints). Methods: The aim of this single-center, retrospective observational study was to evaluate, in 65 COPD patients with recurrent exacerbations, the effects of B/F/G treatment after 18–24 months compared to therapies with LABA/LAMA, ICS/LABA, ICS/LABA + LAMA or other SITT taken in the previous 18–24 months. Results: After 22.8 ± 4.6 months, 20.12 ± 4.24 B/F/G packages were prescribed, while packs of other therapies given in the 23.35 ± 4.7 months (p = 0.587) before using B/F/G were 15.58 ± 9.8 (p = 0.0009). Emergency room visits (0.34 ± 0.56) and hospitalizations (0.52 ± 0.81) during about 2 years of B/F/G therapy were lower compared to the ones during pre-B/F/G treatments (0.65 ± 1.2, p = 0.015 and 0.83 ± 1.25, p = 0.019, respectively). After B/F/G treatment, the mean FEV1% value (48.5 ± 16.7%) was higher compared to that measured after the therapies taken before switching to B/F/G (45 ± 15.3%; p = 0.013). Conversely, there were no differences in FVC% values. OCs (2.96 ± 2.6) and SABA (1.41 ± 2.06) packages prescribed during B/F/G were lower than those observed during pre-B/F/G treatments (3.86 ± 2.35, p = 0.026 and 2.48 ± 4.57, p = 0.046, respectively). No differences in antibiotic prescriptions were observed during both therapies. Conclusions: Our real-life evaluation highlighted that B/F/G treatment may be effective, even in the long term, in reducing exacerbations, OC and SABA consumption and in improving lung function in COPD patients with high persistence/adherence to B/F/G compared to other non-persistent inhaled therapies previously taken. Optimizing treatment adherence should be one important goal of COPD patients’ management to maximize the therapy benefits.

13 September 2022 in Oxygen
Verified
Journal Article
Open access
PDF file
AMAndrea S. Melani
Andrea S. Melani
RRRosa Metella Refini
Rosa Metella Refini
SCSara Croce
Sara Croce
MMMaddalena Messina
Maddalena Messina
This narrative paper reviews the current knowledge of Home Oxygen Therapy (HOT) in stable Chronic Obstructive Pulmonary Disease (COPD) and Interstitial Lung Disease (ILD), two major causes of Long-Term Oxygen Therapy (LTOT) prescription. There is evidence that LTOT improves survival in COPD subjects with chronic severe respiratory failure. HOT is also used to contrast exercise and sleeping hypoxemia and to improve Quality of Life (QoL) and symptoms. Ambulatory Oxygen Therapy (AOT) did not assure generalized improvements in symptoms and Quality of Life (QoL) of COPD subjects. There is short-term evidence in a real-life study that AOT may improve QoL in ILD subjects with Exercise Oxygen Desaturation (EOD) and exertional dyspnea. There are some differences between guidelines and practices, which translate into variations in characteristics and rates of ILD and COPD subjects admitted to LTOT and AOT. Indications on titration of oxygen flow and the best oxygen delivery device for optimal management of AOT in COPD and ILD subjects are often vague or lacking. More work is needed for optimizing and customizing HOT in COPD and ILD subjects.